ArticleJournal of cellular and molecular medicine2025
Therapeutic Efficacy of HPβ-CD-Angiotensin-(1-7) Oral Formulation in Muscle Injury Recovery in Rat.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic Efficacy of HPβ-CD-Angiotensin-(1-7) Oral Formulation in Muscle Injury Recovery in Rat.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
To evaluate the therapeutic effect of oral treatment with HPβ-CD-angiotensin-(1-7) (Ang-(1-7)) on muscle recovery after laceration injury. Wistar rats were divided into four groups: Control (n = 10); HPβ-CD-Ang-(1-7) (n = 10); muscle injury + HPβ-CD (MI + Placebo) (n = 24); and muscle injury + HPβ-CD-Ang-(1-7) (MI + Ang-(1-7)) (n = 24). After 7-21 days of treatment, physical performance, histological features and the expression of pro- and anti-fibrotic genes were evaluated. The MI + Ang-(1-7) group showed improved control of the inflammatory phase and reduced deposition of collagen types I and III compared to MI + Placebo. CTGF gene expression analysis revealed lower levels of pro-fibrotic markers and higher expression of proteins involved in blocking fibrotic pathways. In treadmill tests, MI + Ang-(1-7) animals also showed superior physical performance at all evaluated time points. Oral treatment with Ang-(1-7) is effective in promoting recovery from muscle injuries, particularly fibrotic lesions, while preserving muscle function and enhancing physical performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.